PMB participated in the LSX USA Congress in Boston on September 16–17, where we engaged in dynamic conversations around biotech innovation and next-generation therapeutics. The event provided a valuable platform to connect with leaders in oncology, biologics, and investment, fostering meaningful dialogue on the future of neuro-oncology.
We highlighted Immune12, our groundbreaking marine-sourced complex biologic targeting Glioblastoma (GBM), one of the most aggressive forms of brain cancer. The conference proved to be a productive opportunity to share insights, explore strategic collaborations, and advance our mission to transform outcomes for patients facing GBM.
Visit the LSX World Congress Event website for more information.